c-Kit (A829P)

KIT · Variant type: point · HGVS: p.A829P

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Dasatinib	100.0%	0.0%	87.97
2	Ripretinib	99.8%	0.2%	92.95
3	Ponatinib	99.7%	0.3%	78.23
4	Nintedanib	99.1%	0.9%	90.23
5	Tivozanib	98.3%	1.7%	92.42
6	Fostamatinib	98.0%	2.0%	96.74
7	Erdafitinib	97.5%	2.5%	95.71
8	Axitinib	97.1%	2.9%	93.23
9	Sorafenib	96.6%	3.4%	96.72
10	Pralsetinib	96.4%	3.6%	93.43
11	Pacritinib	96.0%	4.0%	88.64
12	Bosutinib	95.5%	4.5%	87.22
13	Cabozantinib	95.2%	4.8%	92.73
14	Brigatinib	95.1%	4.9%	82.96
15	Apatinib	94.9%	5.1%	97.73
16	Selpercatinib	94.4%	5.6%	96.72
17	Nilotinib	94.1%	5.9%	96.49
18	Regorafenib	92.2%	7.8%	95.99
19	Gilteritinib	91.5%	8.5%	88.97
20	Vandetanib	88.9%	11.1%	95.74
21	Avapritinib	88.5%	11.5%	97.73
22	Fedratinib	87.8%	12.2%	96.21
23	Umbralisib	87.8%	12.3%	98.74
24	Pazopanib	87.1%	12.9%	97.49
25	Sunitinib	86.5%	13.5%	91.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Dasatinib	100.0%	—	—
Ripretinib	99.8%	—	—
Ponatinib	99.7%	—	—
Nintedanib	99.1%	—	—
Tivozanib	98.3%	—	—
Fostamatinib	98.0%	—	—
Erdafitinib	97.5%	—	—
Axitinib	97.1%	—	—
Sorafenib	96.6%	—	—
Pralsetinib	96.4%	—	—
Pacritinib	96.0%	—	—
Bosutinib	95.5%	—	—
Cabozantinib	95.2%	—	—
Brigatinib	95.1%	—	—
Apatinib	94.9%	—	—
Selpercatinib	94.4%	—	—
Nilotinib	94.1%	—	—
Regorafenib	92.2%	—	—
Gilteritinib	91.5%	—	—
Vandetanib	88.9%	—	—
Avapritinib	88.5%	—	—
Fedratinib	87.8%	—	—
Umbralisib	87.8%	—	—
Pazopanib	87.1%	—	—
Sunitinib	86.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.4ms